Aged macular degeneration: current therapeutics for management and promising new drug candidates
| Autor: | Afrah Jalil Abd, Rupinder K. Kanwar, Jagat R. Kanwar |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_specialty genetic structures Angiogenesis media_common.quotation_subject Angiogenesis Inhibitors Macular Degeneration 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Elderly population Drug Discovery medicine Animals Humans Available drugs Intensive care medicine Aged media_common Pharmacology business.industry Macular degeneration medicine.disease eye diseases Surgery 030104 developmental biology Drug Design 030221 ophthalmology & optometry Nanoparticles sense organs business |
| Zdroj: | Drug Discovery Today. 22:1671-1679 |
| ISSN: | 1359-6446 |
| Popis: | In elderly aged related macular degeneration (AMD) is the common eye disease which impairs the vision and most of the time it creates permanent vision loss. Because elderly population constitute the larger percentage among society, visual loss due to AMD has become a growing problem. Despite the advances made in developing therapeutics, there is still no satisfactory treatment. The limitations of the available treatments are due to the absence of potent, non-invasive therapy. Furthermore, part of the available drugs targets angiogenesis and create a hypoxic environment that augment further angiogenesis. Therefore, it is reasonable to consider eye integrity and the correlation between hypoxia and angiogenesis before developing successful drugs. This review highlighted issues regarding the available therapeutic strategies and explored whether AMD can be managed by employing specific nanoformulations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect